A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Irinotecan; Paclitaxel
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 05 Jun 2018 According to trial design presented at 54th Annual Meeting of the American Society of Clinical Oncology, current enrollment: 5 of planned 14 patients in stage I of Part A (6/2017-present).
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.